Why the study?
Recent improvements in prospective and retrospective evidence regarding pathogenesis, multimodality imaging, and novel therapies such as anti-IL-1 agents warranted an updated position paper on the diagnosis and treatment of pericardial diseases.
This position paper provides an update on the evidence-based management of pericardial diseases, highlighting the role of CMR and anti-IL-1 agents.
Answers are grounded in this paper and cite their sources.
Supports CMR-guided diagnosis and anti-IL-1 therapy in refractory inflammatory pericarditis; extends existing guidelines with refined recommendations.
The knowledge of pericardial diseases has now improved, including prospective and retrospective cohort studies focusing on the pathogenesis, diagnosis, treatment, and outcomes. The complex interplay between genetic predisposition (especially for autoinflammatory conditions), inflammation, and autoimmunity is now known to trigger recurrences of pericarditis. Moreover, diagnostic capabilities have improved with the implementation of multimodality imaging, particularly cardiac magnetic resonance (CMR), to detect and monitor pericardial inflammation, to allow diagnosis in more complicated cases, and tailor the duration of therapy based on objective parameters. A new class of drugs, the anti-IL-1 agents, have been introduced for patients with an inflammatory phenotype of presentation, and not responding to conventional anti-inflammatory therapies, including NSAID, colchicine, and corticosteroids. At present, the clinical management of pericardial diseases is definitely on the road of evidence-based medicine with new ongoing European guidelines focusing on the spectrum of inflammatory myocardial and pericardial syndromes.
No takes yet. Share an insight, caveat, or question.
Imazio et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: